PATHEON INC Uncategorized Contracts & Agreements
13 Contracts & Agreements
- Indemnity Agreement (Filed With SEC on January 10, 2014)
- WITNESSETH: (Filed With SEC on January 10, 2014)
- Koninklijke DSM N.V. c/o DSMPharmaceutical Products, Inc. 45 Waterview Boulevard Parsippany, New Jersey 07054 (Filed With SEC on November 19, 2013)
- JLL PARTNERS FUND VI, L.P. 450LEXINGTON AVENUE NEW YORK, NEW YORK (Filed With SEC on November 19, 2013)
- JLL PARTNERS FUND VI, L.P. JLLPARTNERS FUND V, L.P. JLL ASSOCIATES V (PATHEON), L.P. JLL PATHEON CO-INVESTMENT FUND, L.P. 450 LEXINGTON AVENUE NEW YORK, NEWYORK (Filed With SEC on November 19, 2013)
- Patheon Inc. - and - JLL/Delta Patheon Holdings, L.P. ARRANGEMENT AGREEMENT November 18, 2013 TABLE OF CONTENTS (Filed With SEC on November 19, 2013)
- AMENDMENT AGREEMENT (Filed With SEC on March 8, 2013)
- Exhibit 10.3Patheon Pharmaceuticals Services Inc4721 Emperor Blvd., Suite 200Durham, North Carolina 27703 (Filed With SEC on March 8, 2013)
- Schedule A Position Description President, Product and Technology Commercialization (Filed With SEC on February 4, 2013)
- JLL PARTNERS FUND V, L.P. 450 LEXINGTON AVENUE,31st Floor NEW YORK, NEW YORK 10017 October 28, 2012 (Filed With SEC on October 29, 2012)
- James C. Mullen Chief Executive OfficerPatheon U.S. Headquarters4721 Emperor Blvd., Suite 200Durham, North Carolina 27703 (Filed With SEC on June 13, 2012)
- Page1 (Filed With SEC on March 9, 2012)
- U.S. Headquarters4721 Emperor Blvd., Suite 200Durham, North Carolina 27703 (Filed With SEC on December 19, 2011)
